Epitope Mapping of Rituximab Using HisMAP Method.
CD20
His tag
epitope mapping
monoclonal antibody
rituximab
Journal
Monoclonal antibodies in immunodiagnosis and immunotherapy
ISSN: 2167-9436
Titre abrégé: Monoclon Antib Immunodiagn Immunother
Pays: United States
ID NLM: 101590955
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
entrez:
28
2
2022
pubmed:
1
3
2022
medline:
3
3
2022
Statut:
ppublish
Résumé
CD20 is expressed in the B lymphocyte, and an effective target for the detection and treatment of B cell lymphomas. Therefore, CD20 has been studied as a therapeutic target of B cell lymphomas and autoimmune disorders. Specific anti-CD20 monoclonal antibodies (mAbs), such as rituximab, ofatumumab, veltuzumab, and ocaratuzumab, have been developed. Revealing the recognition mechanism of antigen by mAbs could contribute to understanding the function of mAbs and could be useful for the development of vaccine. Rituximab is a mouse-human chimeric anti-CD20 mAb, which was developed and approved for the treatment of the B cell malignancies. Hence, the binding epitope of rituximab for CD20 has been studied. Some reports show that
Identifiants
pubmed: 35225667
doi: 10.1089/mab.2021.0044
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antigens, CD20
0
Epitopes
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM